

Surveillance of results of long-term prophylactic treatment of von Willebrand disease with Wilate®

Submission date 22/08/2008	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered
Registration date 01/09/2008	Overall study status Completed	<input type="checkbox"/> Protocol
Last Edited 04/09/2008	Condition category Haematological Disorders	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Ms Martina Jansen

Contact details

Oberlaaerstrasse 235

Vienna

Austria

1100

+43 (0)1 61032 1208

martina.jansen@octapharma.com

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

WIL-18

Study information

Scientific Title

Acronym

WILCOME

Study objectives

Long-term prophylactic treatment of von Willebrand disease (VWD) patients in clinical practice.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethics approval received from the Ethics Committee of University Hospital Malmö on the 7th August 2008.

Study design

Prospective, open-labelled, international multi-centre post-marketing surveillance

Primary study design

Interventional

Secondary study design

Non randomised controlled trial

Study setting(s)

Not specified

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details below to request patient information material

Health condition(s) or problem(s) studied

von Willebrand's disease

Interventions

Treatment details:

The following dosing regimes are only recommendations, based on the Swedish experience with the long-term prophylaxis in VWD:

1. For mucosal, joint bleeds and menorrhagia, the suggested prophylactic dosing is 30 IU

Wilate® (corresponding to 30 IU FVIII:C)/kg body weight 2 - 3 times/week

2. For gastrointestinal bleeds, the suggested prophylactic dosing is 40 IU Wilate® (40 IU FVIII:C) /kg body weight 2 - 3 times/week

Wilate® is administered as an intravenous bolus injection. Dose and dosing schedule are at the full discretion of the treating physician.

Quality of life:

The Quality of Life assessments performed during the surveillance will include:

1. The patient's self-reported health-related quality of life prior to and during prophylaxis with Wilate using the validated generic instruments WHOQOL-BREF (for adults and/or parents/legal guardians) and KINDL (for children), and
2. A disease-specific VWD-QoL questionnaire (for adults, children and their parents/legal guardians)

Quality of life assessments will be measured prior to the start of the prophylaxis, as well as after 6 and 12 months of treatment.

Intervention Type

Drug

Phase

Phase IV

Drug/device/biological/vaccine name(s)

Wilate®

Primary outcome measure

To assess the bleeding frequency in VWD patients prior to and after introduction of regular prophylactic therapy with the VWF-containing concentrate Wilate®. Outcomes will be measured at baseline, 6 and 12 months after treatment. Please note that the number of days the patients missed school or work, as well as occurred adverse drug reactions are documented when the patient visits his doctor, so outcomes may be measured more frequently than every 6 months.

Secondary outcome measures

1. To describe the joint morbidity prior to and during prophylaxis with Wilate®, using the haemophilia joint health score
2. To monitor absence from school/work prior to and during prophylaxis with Wilate®
3. To evaluate the patient's health-related quality of life prior to and during prophylaxis with Wilate® and the patient's self-reported health status prior to and during prophylaxis with Wilate®, using the validated generic instruments of World Health Organization Quality of Life-BREF (WHOQOL-BREF) (for adults) and the generic children's health-related quality of life (KINDL) (for children), and the disease specific VWD-QoL questionnaire
4. To assess treatment satisfaction and treatment efficacy prior to and during prophylaxis with Wilate®, using a 4-point Verbal Rating Scale (VRS), and the Hemo-SatA treatment questionnaire adapted for VWD (VWD-Sat)
5. To evaluate the tolerability of prophylactic treatment with Wilate®:
 - 5.1. Using a 3-point VRS
 - 5.2. By documenting all possibly related adverse drug reactions by the patients, and
 - 5.3. By assessing and - if applicable - reporting all adverse drug reactions by the treating physician occurring during the treatment period with Wilate®

Outcomes will be measured at baseline, 6 and 12 months after treatment. Please note that the number of days the patients missed school or work, as well as occurred adverse drug reactions are documented when the patient visits his doctor, so outcomes may be measured more frequently than every 6 months.

Overall study start date

01/09/2008

Completion date

01/01/2013

Eligibility

Key inclusion criteria

1. Male and female patients of any age
2. Suffering from congenital VWD
3. In need of replacement therapy with factor concentrate
4. Patients starting with a prophylactic treatment must have documentation of at least three apparently spontaneous bleeding episodes (any bleeding site and treated with factor concentrate) in the 6 months prior to enrolment
5. Patients switching from a prophylactic treatment with another factor concentrate to prophylaxis with Wilate® should have anamnesis of bleeds with respective documentation in the period of 12 months prior to enrolment

Participant type(s)

Patient

Age group

Not Specified

Sex

Both

Target number of participants

24

Key exclusion criteria

1. Presence of a bleeding disorder other than VWD
2. History of non-compliance
3. Difficulties in achieving venous access that would prohibit prophylaxis
4. Incapability to follow the requirements of the surveillance, e.g. unable to keep a patient diary

Date of first enrolment

01/09/2008

Date of final enrolment

01/01/2013

Locations

Countries of recruitment

Austria

Germany

Russian Federation

Sweden

Study participating centre

Oberlaaerstrasse 235

Vienna

Austria

1100

Sponsor information

Organisation

Octapharma AG (Switzerland)

Sponsor details

Seidenstrasse 2

Lachen

Switzerland

8853

+41 (0)55 4512140

robert.kuhelj@octapharma.ch

Sponsor type

Industry

Website

<http://www.octapharma.com>

ROR

<https://ror.org/002k5fe57>

Funder(s)

Funder type

Industry

Funder Name

Octapharma AG (Switzerland)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date**Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration